Meg Barbor

2 months ago | theoncologypharmacist.com | Karen Blum |Richard Reich |Meg Barbor |Wayne Kuznar

By Sara Erickson, PharmD, BCACP; Anna Bartoo, PharmD, BCPS; Amy Wallingford, PharmD; Susan Wescott, MBA, RPh; Chelsee Jensen, PharmD, BCPS, P-RCM, RPhBiosimilars offer a significant opportunity for cost-savings yet present logistical hurdles for optimal implementation. Biosimilar savings nationwide are estimated to be $54 billion from 2017 to 2026, but these savings hinge on industry, regulatory, and policy changes to strengthen competition and sustainability in the biosimilar marketplace.

Dec 5, 2024 | espanol.medscape.com | Meg Barbor

El American College of Obstetricians and Gynecologists (ACOG) ha actualizado sus recomendaciones de detección del cáncer de mama y sugiere que las personas con un riesgo promedio de presentar cáncer de mama comiencen a hacerse una mamografía a los 40 años.

Oct 25, 2024 | oncpracticemanagement.com | Jason Lockard |Meg Barbor

Korinne G. Lee, MSN, FNP-C1; Amanda Pate, MSN, RN-BC, OCN, ONS1; Bob Gold2; Jeff Rusk1; Chevon Rariy, MD1 1Oncology Care Partners; 2GoMo Health Providing oncology care outside the clinic walls, where most side effects take place, can be extremely challenging.

Oct 18, 2024 | mdedge.com | Meg Barbor

The American College of Obstetricians and Gynecologists (ACOG) has updated its breast cancer screening guidelines, recommending that individuals at an average risk for breast cancer initiate mammography screening at age 40. This change reflects evolving evidence that starting earlier screening yields greater net benefits in reducing breast cancer mortality, particularly for certain racial groups with higher risk factors.

Sep 6, 2024 | theoncologypharmacist.com | Meg Barbor |Charlie Dawson |Chase Doyle

"Encourage Your Patients to Participate! US-Based Clinical Trials That Are Actively Recruiting in Ovarian Cancer" was originally published by Oncology Practice Management. Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups.